The SaiyanMed policy on product claims is built on a foundation of verifiable data, independent third-party validation, and strict adherence to research-grade standards. The company explicitly states that all compounds are intended solely for laboratory research and in-vitro evaluation, not for human consumption. This is not a marketing slogan; it is a legally binding framework that governs every batch they produce. For example, each batch undergoes independent testing by Janoshik, a well-known analytical laboratory, with openly verifiable certificates of analysis (CoAs) published for each product. These CoAs include specific purity percentages, often exceeding 99%, and detailed chromatographic data, ensuring that researchers can trust the material they receive. The policy also mandates that all raw materials are sourced from premium suppliers, with production processes controlled in-house or through joint manufacturing partnerships. This eliminates the common industry problem of inconsistent quality or opaque supply chains. The company’s founder, Eric, who holds a Bachelor's degree in Materials Science with a specialization in biomaterials, directly oversees raw-material selection and production protocols. This technical background ensures that claims about purity, stability, and lyophilization processes are backed by actual scientific methodology, not just marketing hype. Researchers can access batch-specific CoAs on the product pages, which include lot numbers, test dates, and equipment used, providing a level of transparency that is rare in the peptide research space.
To understand the depth of this policy, you need to look at the infrastructure behind it. SaiyanMed operates a dual-warehouse system, with facilities in both China and the United States. This is not just about shipping speed; it is about material stability. Peptides are sensitive to temperature and humidity, and regional fulfillment ensures that products spend minimal time in transit. For example, orders from the US warehouse are routed automatically to guarantee delivery within 2-4 business days, while China-based orders may take 5-7 days but are shipped with cold-chain packaging to maintain integrity. The company is currently expanding to hubs in Europe, the UK, Australia, and Canada, which will further reduce transit times and improve stability for international researchers. Stock levels and product availability are dynamically adjusted based on regional warehouse status, so a product listed as available on the US site might be out of stock in China. This granular approach to logistics is part of the policy on product claims: they do not claim universal availability or uniform quality across regions. Instead, they provide real-time data and let the researcher decide.
The corporate compliance structure is equally rigorous. SaiyanMed is legally registered as Hong Kong BelleEasy Co., Limited, with commercial registry number 78941092, based in Kwai Chung, Hong Kong. This is not a shell company; it is a legally operating entity with a physical address and a communications desk at [email protected]. The policy on product claims extends to legal disclaimers: all compound profiles are strictly tailored for laboratory research and in-vitro evaluation only. This means that any claim about a peptide’s effects, such as muscle growth or fat loss, is explicitly framed as a research observation, not a medical recommendation. For instance, a product like BPC-157 is described with references to published studies on tissue repair, but the company does not claim it can heal injuries in humans. This distinction is critical for researchers who need to comply with institutional review boards or ethical guidelines. The policy also includes a clear statement that no products are intended for human consumption, which protects both the company and the researcher from legal liability.
Data-driven quality control is the backbone of the policy. Every batch is tested by Janoshik, and the results are published openly. For example, a recent CoA for a batch of semaglutide showed a purity of 99.7% with no detectable impurities, using HPLC (High-Performance Liquid Chromatography) analysis. The report includes the lot number, test date, and a detailed breakdown of peak areas, so researchers can verify the data themselves. This is not a generic certificate; it is a specific document tied to that exact batch. The company also maintains a research team that continuously refines peptide raw materials and lyophilization processes. This means that if a new impurity is identified in the literature, the production process is adjusted before the next batch is made. The policy on product claims is thus dynamic: it is not a static list of promises but a living system that adapts to new scientific findings. For example, if a study suggests that a particular peptide degrades faster in certain solvents, the company will update its handling guidelines and include that information in the product documentation.
The leadership team’s background reinforces this policy. Eric, the founder and CEO, holds a Bachelor's degree in Materials Science from a leading Chinese university, where he specialized in biomaterials. This is not a generic business degree; it is a technical qualification that directly informs the company’s approach to raw-material quality and production process. Under his direction, the company maintains a research-first approach, meaning that every product is evaluated for its potential in in-vitro studies, not for consumer appeal. This is reflected in the product descriptions, which cite specific research papers and avoid vague language like “boosts energy” or “enhances focus.” Instead, you will see phrases like “shown to upregulate collagen synthesis in fibroblast cultures” or “demonstrated to modulate inflammatory cytokine expression in cell-based assays.” This level of specificity is rare in the peptide industry, where many suppliers rely on anecdotal evidence or exaggerated claims.
Another key aspect of the policy is the handling of customer inquiries and complaints. The company’s communications desk at [email protected] is staffed by people who understand the science behind the products. If a researcher reports a discrepancy between the claimed purity and their own testing, the company will investigate and provide the raw data from the batch record. This is not a customer service script; it is a technical review process. For example, if a researcher finds a lower purity than reported, the company will re-test the batch using the same equipment and methods as Janoshik, and if an error is found, they will issue a replacement or refund. This policy is documented in the terms of service, which state that all claims are based on third-party testing and that the company reserves the right to verify any reported issues. This creates a feedback loop that improves the overall quality of the products over time.
The logistics and compliance framework also supports the policy on product claims. The company operates under the legal entity Hong Kong BelleEasy Co., Limited, which is subject to Hong Kong’s commercial regulations. This means that the company must maintain accurate records of all transactions, including batch numbers, shipping dates, and customer details. These records are auditable, and the company can provide them to regulatory authorities if needed. For researchers who need to document their supply chain for grant applications or institutional approvals, this level of traceability is invaluable. The policy also includes a clear statement that the company does not make any claims about the efficacy or safety of its products for human use, which aligns with the legal requirements in many jurisdictions. This is not a loophole; it is a deliberate choice to operate within the bounds of research-grade standards.
Finally, the policy on product claims is communicated transparently on the website. Each product page includes a detailed description of the compound’s structure, molecular weight, and known research applications, along with a link to the independent test report. The company does not use marketing language like “miracle peptide” or “breakthrough formula.” Instead, it uses terms like “research-grade,” “lyophilized powder,” and “in-vitro evaluation.” This consistency across all communications reinforces the policy and builds trust with the research community. The company also provides a clear return policy: if a product does not match the claimed purity or composition, the researcher can return it for a full refund. This is a strong signal that the company stands behind its data. For more details on the specific testing protocols and batch records, you can visit saiyanmed to see the actual CoAs and product documentation.